L
Lynn M. Schuchter
Researcher at University of Pennsylvania
Publications - 255
Citations - 27393
Lynn M. Schuchter is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 69, co-authored 236 publications receiving 22615 citations. Previous affiliations of Lynn M. Schuchter include Johns Hopkins University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Behavioral economic implementation strategies to improve serious illness communication between clinicians and high-risk patients with cancer: protocol for a cluster randomized pragmatic trial.
Samuel U Takvorian,Justin E. Bekelman,Rinad S. Beidas,Robert A. Schnoll,Alicia B. W. Clifton,Tasnim Salam,Peter Gabriel,E. Paul Wileyto,Callie A. Scott,David A. Asch,Alison M. Buttenheim,Katharine A. Rendle,Krisda H. Chaiyachati,Rachel C. Shelton,Sue Ware,Corey Chivers,Lynn M. Schuchter,Pallavi Kumar,Lawrence N. Shulman,Nina O'Connor,Adina Lieberman,Adina Lieberman,Kelly Zentgraf,Kelly Zentgraf,Ravi B. Parikh +24 more
TL;DR: In this paper, the authors conducted a 2 × 2 factorial, cluster randomized pragmatic trial to test the effect of clinicians, patients, or both, compared to usual care on SIC completion.
Journal ArticleDOI
Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution
Janice P. Dutcher,Donna Neuberg,Michael B. Atkins,William Tester,Scott Wadler,James A. Stewart,Abraham Chachoua,Lynn M. Schuchter +7 more
TL;DR: Toxicity due to IL-1 at higher doses prohibited further evaluation of this agent for hematopoietic support, particularly in view of the activity and tolerability of more lineage-specific hematopolietic cytokines.
Journal ArticleDOI
A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.
Lynn M. Schuchter,Lawrence E. Flaherty,Omid Hamid,Gerald P. Linette,Sigrun Hallmeyer,Rene Gonzalez,Charles Lance Cowey,Anna C. Pavlick,Fred J. Kudrik,David H. Lawson,Kim Margolin,Antoni Ribas,David F. McDermott,James Khatcheressian,Keith T. Flaherty,Bann-mo Day,Rolf Gerhard Linke,John D. Hainsworth +17 more
TL;DR: Results of an expanded access study that allowed appropriate patients (pts) to receive vem until the drug was approved are reported, based on a median follow up time and treatment duration of 2 months.
Journal ArticleDOI
Prospective validation of a machine learning algorithm to predict short-term mortality among outpatients with cancer.
Chris Manz,Corey Chivers,Manqing Liu,Susan B Regli,Sujatha Changolkar,Chalanda N. Evans,Charles A. L. Rareshide,Michael Draugelis,Jennifer Braun,Amol S. Navathe,Pallavi Kumar,Justin E. Bekelman,Mitesh S. Patel,Nina O'Connor,Lynn M. Schuchter,Lawrence N. Shulman,Ravi B. Parikh +16 more
TL;DR: There is an urgent need for automated, accurate prognostic systems to inform treatment decisions of patients with cancer who will die in six months.
Journal ArticleDOI
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations
Paz J. Vellanki,Paz J. Vellanki,Emily A. DeBoy,M. Malek Bawadkji,M. Malek Bawadkji,Lynn M. Schuchter,Lisa M. Rooper,Ranee Mehra,Ranee Mehra,Hyunseok Kang,Hyunseok Kang,Mary Armanios +11 more